Faculty, Staff and Student Publications
Publication Date
6-15-2022
Journal
Journal of Translational Medicine
Abstract
After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgical morbidity, early eradication of micrometastases and prevention of distant disease, and greater antigen-specific T cell response. For some cancers, pathologic response has been established as a surrogate measure for long-term outcomes, therefore offering the ability for early and objective assessment of treatment efficacy and the potential to inform and personalize adjuvant treatment clinical decision-making. Leveraging the neoadjuvant treatment setting offers the ability to deeply interrogate longitudinal tissue in order to gain translatable, pan-malignancy insights into response and mechanisms of resistance to immunotherapy. Neoadjuvant immunotherapy across cancers was a focus of discussion at the virtual Immunotherapy Bridge meeting (December 1-2, 2021). Clinical, biomarker, and pathologic insights from prostate, breast, colon, and non-small-cell lung cancers, melanoma and non-melanoma skin cancers were discussed and are summarized in this report.
Keywords
Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Male, Melanoma, Neoadjuvant Therapy, Immunotherapy, Checkpoint inhibitors, PD-1, CTLA-4, Neoadjuvant, Pathological response
DOI
10.1186/s12967-022-03472-x
PMID
35706041
PMCID
PMC9199148
PubMedCentral® Posted Date
6-15-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Immunotherapy Commons, Medical Genetics Commons, Oncology Commons, Translational Medical Research Commons